Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

32 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment.
van der Horst HJ, de Jonge AV, Hiemstra IH, Gelderloos AT, Berry DRAI, Hijmering NJ, van Essen HF, de Jong D, Chamuleau MED, Zweegman S, Breij ECW, Roemer MGM, Mutis T. van der Horst HJ, et al. Blood Cancer J. 2021 Feb 18;11(2):38. doi: 10.1038/s41408-021-00430-6. Blood Cancer J. 2021. PMID: 33602901 Free PMC article.
CD20 and CD37 antibodies synergize to activate complement by Fc-mediated clustering.
Oostindie SC, van der Horst HJ, Lindorfer MA, Cook EM, Tupitza JC, Zent CS, Burack R, VanDerMeid KR, Strumane K, Chamuleau MED, Mutis T, de Jong RN, Schuurman J, Breij ECW, Beurskens FJ, Parren PWHI, Taylor RP. Oostindie SC, et al. Among authors: van der horst hj. Haematologica. 2019 Sep;104(9):1841-1852. doi: 10.3324/haematol.2018.207266. Epub 2019 Feb 21. Haematologica. 2019. PMID: 30792198 Free PMC article.
Preclinical evidence for an effective therapeutic activity of FL118, a novel survivin inhibitor, in patients with relapsed/refractory multiple myeloma.
Holthof LC, van der Horst HJ, van Hal-van Veen SE, Ruiter RWJ, Li F, Buijze M, Andersen MN, Yuan H, de Bruijn J, van de Donk NWCJ, Lokhorst HM, Zweegman S, Groen RWJ, Mutis T. Holthof LC, et al. Among authors: van der horst hj. Haematologica. 2020 Jan 31;105(2):e80-e83. doi: 10.3324/haematol.2018.213314. Print 2020. Haematologica. 2020. PMID: 31123033 Free PMC article. No abstract available.
DuoHexaBody-CD37®, a novel biparatopic CD37 antibody with enhanced Fc-mediated hexamerization as a potential therapy for B-cell malignancies.
Oostindie SC, van der Horst HJ, Kil LP, Strumane K, Overdijk MB, van den Brink EN, van den Brakel JHN, Rademaker HJ, van Kessel B, van den Noort J, Chamuleau MED, Mutis T, Lindorfer MA, Taylor RP, Schuurman J, Parren PWHI, Beurskens FJ, Breij ECW. Oostindie SC, et al. Among authors: van der horst hj. Blood Cancer J. 2020 Apr 28;10(3):30. doi: 10.1038/s41408-020-0292-7. Blood Cancer J. 2020. PMID: 32341336 Free PMC article.
Potent Preclinical Efficacy of DuoHexaBody-CD37 in B-Cell Malignancies.
van der Horst HJ, Oostindie SC, Cillessen SAGM, Gelderloos AT, Overdijk MB, Nijhof IS, Zweegman S, Chamuleau MED, Breij ECW, Mutis T. van der Horst HJ, et al. Hemasphere. 2020 Dec 9;5(1):e504. doi: 10.1097/HS9.0000000000000504. eCollection 2021 Jan. Hemasphere. 2020. PMID: 33324950 Free PMC article.
Bone Marrow Mesenchymal Stromal Cell-mediated Resistance in Multiple Myeloma Against NK Cells can be Overcome by Introduction of CD38-CAR or TRAIL-variant.
Holthof LC, Stikvoort A, van der Horst HJ, Gelderloos AT, Poels R, Li F, Groen RWJ, Zweegman S, van de Donk NWCJ, O'Dwyer M, Mutis T. Holthof LC, et al. Among authors: van der horst hj. Hemasphere. 2021 Apr 21;5(5):e561. doi: 10.1097/HS9.0000000000000561. eCollection 2021 May. Hemasphere. 2021. PMID: 33898931 Free PMC article.
32 results